In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kaletra Tablets Offer Convenience Benefits, Abbott Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm plans to transition all patients on Kaletra (lopinavir/ritonavir) capsules to the new tablet formulation, which reduces the pill count and eliminates the need for refrigeration.

You may also be interested in...



Abbott's HIV Therapy Kaletra Gets Once-Daily Dosing

A once-daily dosing regimen of 800 mg lopinavir/200 mg ritonavir for treatment-naïve patients is approved based on two clinical trials comparing once- and twice-daily regimens in HIV-1 infected patients. Once-daily administration is not recommended for treatment-experienced patients, labeling states.

Deal Watch: Allergan Keeps After Hair Loss With Exicure Deal

Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.

An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer

CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.

Topics

UsernamePublicRestriction

Register

PS061199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel